EFLETIRIZINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H24F2N2O3
Molecular Weight	390.4237
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)COCCN1CCN(CC1)C(C2=CC=C(F)C=C2)C3=CC=C(F)C=C3

InChI

InChIKey=BAWMMJAUVBLLEE-UHFFFAOYSA-N

InChI=1S/C21H24F2N2O3/c22-18-5-1-16(2-6-18)21(17-3-7-19(23)8-4-17)25-11-9-24(10-12-25)13-14-28-15-20(26)27/h1-8,21H,9-15H2,(H,26,27)

HIDE SMILES / InChI

Molecular Formula	C21H24F2N2O3
Molecular Weight	390.4237
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11829715
Curator's Comment: description was created based on several sources, including: http://www.pharmacodia.com/yaodu/html/v1/chemicals/9c3368c58b7c3569a3e83048cfc8d023.html

Efletirizine is histamine H1 receptor antagonist. Restricted to topical use. It was under investigation in Phase III (in Europe) clinical studies for the treatment of allergic rhinitis and chronic idiopathic urticarial. Research was discontinued in 2005 due to limited clinical efficacy and safety data. Efletirizine also reduced ocular itching.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 316 Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11829715	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Allergic rhinitis 104 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11829715 https://www.google.com/patents/US20070185122	Palliative		Phase III 665	Unknown Approved Use Unknown
Chronic idiopathic urticaria 11 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11829715	Palliative		Phase III 665	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
Alfa Chemistry	71558	http://www.alfa-chemistry.com/search.aspx?q=71558
Alfa Chemistry	ACM150756357	http://www.alfa-chemistry.com/search.aspx?q=ACM150756357
Compound Cloud	156659
Compound Cloud	66003
MolPort	MolPort-002-506-273	https://www.molport.com/shop/molecule-link/MolPort-002-506-273
MuseChem	M100689	https://www.musechem.com/product/M100689.html

PubMed

Title	Date	PubMed
Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.	2004-11-15	15482930
Antihistamines in late-phase clinical development for allergic disease.	2002-02	11829715
Quantitation of efletirizine in human plasma and urine using automated solid-phase extraction and column-switching high-performance liquid chromatography.	1999-07-09	10448959

Patents

Sample Use Guides

In Vivo Use Guide

15, 30 and 60 ug/100 ul (0.15%, 0.3% or 0.6%) twice-daily for two weeks

Route of Administration: Topical

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:25:04 GMT 2025` Edited by `admin` on `Mon Mar 31 18:25:04 GMT 2025`
Record UNII	B6C301298G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

(2-(4-(BIS(P-FLUOROPHENYL)METHYL)-1-PIPERAZINYL)ETHOXY)ACETIC ACID

Preferred Name

English

EFLETIRIZINE

Official Name

English

efletirizine [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29578